Immunotherapy for prostate cancer

被引：13

作者：

Fong L. ^{[1
]}

Small E.J. ^{[1
]}

机构：

[1] University of California, San Francisco, San Francisco, CA 94143-0511

来源：

Current Oncology Reports | 2007年 / 9卷 / 3期

关键词：

Prostate Cancer; Advanced Prostate Cancer; Prostatic Acid Phosphatase; Prostate Stem Cell Antigen; Provenge;

D O I：

10.1007/s11912-007-0026-z

中图分类号：

学科分类号：

摘要：

Whereas androgen deprivation and chemotherapy have become the cornerstone of therapy for advanced prostate cancer, novel therapies are being developed that may expand upon currently available treatments. The identification of antigens expressed by prostate tissue and/or prostate cancer that are recognized by T cells or antibodies creates opportunities to develop novel immunotherapeutic approaches including tumor vaccines. Proteins expressed in prostate cancer - including prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen - have been used as immunologic targets for immunotherapy. Moreover, innovations in cancer genomics and proteomics also will aid in the identification of immunologic targets. Emerging trials have demonstrated that immunotherapy may generate not only immune responses in patients but also clinical responses. Future studies will be directed at capitalizing on these findings. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：226 / 233

页数：7

共 62 条

[1]

Wang X., Yu J., Sreekumar A., Et al., Autoantibody signatures in prostate cancer, N Engl J Med, 53, pp. 1224-1235, (2005)

[2]

Van Parijs L., Abbas A.K., Homeostasis and self-tolerance in the immune system: Turning lymphocytes off, Science, 280, pp. 243-248, (1998)

[3]

Fong L., Engleman E.G., Dendritic Cells in cancer immunotherapy, Annu Rev Immunol, 18, pp. 245-273, (2000)

[4]

Hudson M.A., Bahnson R.R., Catalona W.J., Clinical use of prostate-specific antigen in patients with prostate cancer, J Urol, 142, pp. 1011-1017, (1989)

[5]

Plowman P.N., Perry L.A., Chard T., Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer, Br J Urol, 59, pp. 255-257, (1987)

[6]

Storlie J.A., Buckner J.C., Wiseman G.A., Et al., Prostate-specific antigen levels and clinical response to low-dose dexamethasone for hormone-refractory metastatic prostate carcinoma, Cancer, 76, pp. 96-100, (1995)

[7]

Small E.J., McMillan A., Meyer M., Et al., Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival, J Clin Oncol, 19, pp. 1304-1311, (2001)

[8]

Schmid H.P., McNeal J.E., Stamey T.A., Observations on the doubling time of prostate cancer the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume, Cancer, 71, pp. 2031-2040, (1993)

[9]

Slovin S.F., Scher H.I., Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man - clinical trials at Memorial Sloan-Kettering Cancer Center, Semin Oncol, 26, pp. 448-454, (1999)

[10]

Fong L., Brockstedt D., Benike C., Et al., Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy, J Immunol, 167, pp. 7150-7156, (2001)

← 1 2 3 4 5 6 7 →